A recent study has shown that sacubitril/valsartan can significantly improve stress-induced myocardial fibrosis by regulating atrial natriuretic peptide-induced PKG signaling in cardiac fibroblasts and inhibiting the expression of fibroblast transformation-related processes, which are not generated by treatment with the molar equivalent of valsartan (Burke et al., 2019), and our results are consistent with these changes. Here, NPPA is linked to Myocardial fibrosis.